Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

D. I. Daikh, D. Wofsy

Research output: Contribution to journalArticlepeer-review

176 Scopus citations

Abstract

Cyclophosphamide (CTX) prevents progression of nephritis and prolongs survival in (NZB x NZW)F1 (B/W) mice and is used to treat humans with lupus nephritis. To compare the efficacy of CTLA4Ig with CTX and determine whether there is an incremental benefit to combining CTLA4Ig with CTX, we treated B/W mice with CTX, CTLA4Ig, or both agents. In mice with mild renal disease, treatment delayed the onset of proteinuria and prolonged survival in all groups. In mice with advanced renal disease, treatment with both agents reduced proteinuria in 71% of mice, whereas mice treated with either agent alone had no such improvement. Survival was also markedly improved among mice treated with both agents. Thus, combination treatment with CTX and CTLA4Ig is more effective than either agent alone in reducing renal disease and prolonging survival of B/W mice with advanced nephritis. This striking reversal of proteinuria is unprecedented in animal models of SLE.

Original languageEnglish (US)
Pages (from-to)2913-2916
Number of pages4
JournalJournal of Immunology
Volume166
Issue number5
DOIs
StatePublished - Mar 1 2001
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Cutting edge: Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide'. Together they form a unique fingerprint.

Cite this